$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

$plrx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000174647324000043 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$1.580M
YoY Change	-100.0%	-100.0%	-83.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.25M	$13.85M	$57.93M
YoY Change	7.72%	-2.79%	45.0%
% of Gross Profit
Research & Development	$37.15M	$33.18M	$127.8M
YoY Change	26.9%	32.13%	31.84%
% of Gross Profit
Depreciation & Amortization	$500.0K	$464.0K	$1.800M
YoY Change	0.0%	1.98%	0.0%
% of Gross Profit
Operating Expenses	$52.39M	$47.04M	$185.7M
YoY Change	20.64%	19.49%	35.68%
Operating Profit	-$52.39M		-$184.1M
YoY Change	24.46%		44.77%
Interest Expense	$445.0K	$5.928M	$1.267M
YoY Change	43.09%	153.33%	-67.34%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$46.96M	-$41.11M	-$161.3M
YoY Change	25.05%	17.25%	30.82%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$46.96M	-$41.11M	-$161.3M
YoY Change	25.05%	17.25%	30.83%
Net Earnings / Revenue			-10211.14%
Basic Earnings Per Share	-$0.78		-$2.75
Diluted Earnings Per Share	-$0.78	-$0.69	-$2.75
COMMON SHARES
Basic Shares Outstanding	60.24M shares	59.90M shares	58.72M shares
Diluted Shares Outstanding	60.18M shares		58.72M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$482.4M	$494.2M	$494.2M
YoY Change	-16.44%	49.23%	49.23%
Cash & Equivalents	$114.3M	$63.23M	$63.23M
Short-Term Investments	$368.1M	$431.0M	$431.0M
Other Short-Term Assets	$5.194M	$8.260M	$8.260M
YoY Change	-15.63%	17.03%	17.03%
Inventory
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$2.997M	$2.997M
Total Short-Term Assets	$489.9M	$505.5M	$505.5M
YoY Change	-16.72%	48.54%	48.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.605M	$3.567M	$4.778M
YoY Change	33.55%	-20.49%	-51.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$392.0K	$392.0K	$1.874M
YoY Change	-39.13%	-0.51%	375.63%
Total Long-Term Assets	$31.71M	$6.652M	$6.652M
YoY Change	228.43%	-35.43%	-35.43%
TOTAL ASSETS
Total Short-Term Assets	$489.9M	$505.5M	$505.5M
Total Long-Term Assets	$31.71M	$6.652M	$6.652M
Total Assets	$521.6M	$512.2M	$512.2M
YoY Change	-12.76%	46.07%	46.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.327M	$4.531M	$4.531M
YoY Change	416.35%	186.77%	186.77%
Accrued Expenses	$5.868M	$10.22M	$23.99M
YoY Change	-73.0%	-54.24%	7.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.39M	$28.52M	$28.52M
YoY Change	31.26%	19.28%	19.28%
LONG-TERM LIABILITIES
Long-Term Debt	$30.00M	$10.05M	$10.05M
YoY Change	201.29%	1.26%	1.26%
Other Long-Term Liabilities	$23.88M	$0.00	$0.00
YoY Change	737.89%	-100.0%	-100.0%
Total Long-Term Liabilities	$53.88M	$10.05M	$10.05M
YoY Change	320.69%	-24.73%	-24.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.39M	$28.52M	$28.52M
Total Long-Term Liabilities	$53.88M	$10.05M	$10.05M
Total Liabilities	$84.27M	$38.58M	$38.58M
YoY Change	134.35%	3.51%	3.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$546.7M	-$499.7M
YoY Change	45.42%	47.67%
Common Stock	$984.5M	$973.0M
YoY Change	4.82%	48.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$437.3M	$473.6M	$473.6M
YoY Change
Total Liabilities & Shareholders Equity	$521.6M	$512.2M	$512.2M
YoY Change	-12.76%	46.07%	46.07%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$46.96M	-$41.11M	-$161.3M
YoY Change	25.05%	17.25%	30.83%
Depreciation, Depletion And Amortization	$500.0K	$464.0K	$1.800M
YoY Change	0.0%	1.98%	0.0%
Cash From Operating Activities	-$30.27M	-$25.10M	-$116.4M
YoY Change	-0.02%	-19.65%	22.96%
INVESTING ACTIVITIES
Capital Expenditures	$1.492M	$61.00K	$921.0K
YoY Change	815.34%	-63.25%	-47.67%
Acquisitions
YoY Change
Other Investing Activities	$61.04M	$31.98M	-$126.1M
YoY Change	-135.07%	58.42%	-15.06%
Cash From Investing Activities	$59.55M	$31.92M	-$127.0M
YoY Change	-134.18%	59.43%	-15.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$21.79M	219.0K	$274.4M
YoY Change	-92.03%	-22.89%	20.96%
NET CHANGE
Cash From Operating Activities	-$30.27M	-25.10M	-$116.4M
Cash From Investing Activities	$59.55M	31.92M	-$127.0M
Cash From Financing Activities	$21.79M	219.0K	$274.4M
Net Change In Cash	$51.06M	7.038M	$31.03M
YoY Change	-25.83%	-164.37%	-272.58%
FREE CASH FLOW
Cash From Operating Activities	-$30.27M	-$25.10M	-$116.4M
Capital Expenditures	$1.492M	$61.00K	$921.0K
Free Cash Flow	-$31.76M	-$25.16M	-$117.3M
YoY Change	4.35%	-19.88%	21.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1360000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001746473
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39303
CY2023	dei	Entity Registrant Name EntityRegistrantName	PLIANT THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4272481
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Littlefield Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	481-6770
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	PLRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1008132383	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60239176	shares
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	San Francisco, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63234000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33685000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	431011000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	297502000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1983000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11257000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7058000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	505502000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	340311000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3567000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4486000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1211000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5422000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1482000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	392000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	394000	usd
CY2023Q4	us-gaap	Assets Assets	512154000	usd
CY2022Q4	us-gaap	Assets Assets	350613000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4531000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1580000	usd
CY2023Q4	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	12456000	usd
CY2022Q4	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	11218000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10219000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8658000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1318000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2457000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28524000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23913000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3429000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	10054000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	9929000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	38578000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	37271000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59921002	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59921002	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48941254	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48941254	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	972973000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	653707000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-499748000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-338412000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	345000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1958000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	473576000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	313342000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	512154000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	350613000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1580000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9685000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7572000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127797000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96936000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77549000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57928000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39949000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27558000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	185725000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	136885000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	105107000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-184145000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-127200000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-97535000	usd
CY2023	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	24076000	usd
CY2022	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	4670000	usd
CY2021	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	272000	usd
CY2023	us-gaap	Interest Expense InterestExpense	1267000	usd
CY2022	us-gaap	Interest Expense InterestExpense	791000	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-161336000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123321000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-97263000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.94
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.71
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.71
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35846421	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35846421	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	283061000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	2984000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	9000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	215401000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22598000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1757000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123321000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	313342000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	269782000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	5002000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44483000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2303000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-161336000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	473576000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-161336000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-123321000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-97263000	usd
CY2023	us-gaap	Depreciation Depreciation	1841000	usd
CY2022	us-gaap	Depreciation Depreciation	1823000	usd
CY2021	us-gaap	Depreciation Depreciation	1535000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	44483000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22598000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10437000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2390000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1858000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1669000	usd
CY2023	plrx	Accretion Amortization Of Discounts And Premiums Investments And Debt AccretionAmortizationOfDiscountsAndPremiumsInvestmentsAndDebt	4990000	usd
CY2022	plrx	Accretion Amortization Of Discounts And Premiums Investments And Debt AccretionAmortizationOfDiscountsAndPremiumsInvestmentsAndDebt	1806000	usd
CY2021	plrx	Accretion Amortization Of Discounts And Premiums Investments And Debt AccretionAmortizationOfDiscountsAndPremiumsInvestmentsAndDebt	-1262000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1983000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7281000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3735000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	294000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2266000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-201000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-70000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2969000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1351000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	891000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2781000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7904000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2695000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2747000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2258000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1754000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-116361000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-94631000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-75443000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	583069000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	325716000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	456978000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1953000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-150204000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	73699000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	270251000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	216201000	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	5001000	usd
CY2022	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	1360000	usd
CY2021	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	2984000	usd
CY2023	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	847000	usd
CY2022	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	557000	usd
CY2021	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	457000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	274405000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	226854000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2527000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31032000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17981000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	783000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51665000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50882000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64716000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33684000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51665000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1149000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	615000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q4	plrx	Cash And Cash Equivalents At Carrying Value Rounded CashAndCashEquivalentsAtCarryingValueRounded	63234000	usd
CY2022Q4	plrx	Cash And Cash Equivalents At Carrying Value Rounded CashAndCashEquivalentsAtCarryingValueRounded	33684000	usd
CY2021Q4	plrx	Cash And Cash Equivalents At Carrying Value Rounded CashAndCashEquivalentsAtCarryingValueRounded	51665000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1482000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64716000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33684000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51665000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2303000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1757000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-169000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	usd
CY2023	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	0	usd
CY2022	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	2000	usd
CY2021	plrx	Reclassification Of Restricted Stock Awards From Liabilities To Common Stock Upon Vesting ReclassificationOfRestrictedStockAwardsFromLiabilitiesToCommonStockUponVesting	9000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3846000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2657000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2400000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	950000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	plrx	Decrease In Right Of Use Assets And Liabilities From Lease Modifications DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications	1821000	usd
CY2022	plrx	Decrease In Right Of Use Assets And Liabilities From Lease Modifications DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications	0	usd
CY2021	plrx	Decrease In Right Of Use Assets And Liabilities From Lease Modifications DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development costs, fair value of assets, stock-based compensation, income taxes and uncertain tax positions. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, however, actual results may differ from those estimates.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. The Company invests in money market funds, U.S. Treasury securities, government notes and corporate debt securities. The Company limits its credit risk associated with its cash and cash equivalents by placing them with banks and institutions it believes are highly credit worthy and in highly rated investments. However, the Company had deposits in excess of the Federal Deposit Insurance Corporation (“FDIC”) </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insured limit of $250,000. The Company performs credit evaluations of its customer, and the risk with respect to accounts receivable is further mitigated by the short duration of customer payment terms, generally within 60 days, and the pedigree of the customer base. During the years ended December 31, 2023, 2022 and 2021, Novartis accounted for 100% of the Company’s revenue and accounts receivable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results of operations involve several other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products, including those that may be developed or marketed by larger companies, securing and protecting intellectual property, strategic relationships and dependence on key individuals and sole source suppliers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span></div>
CY2023	plrx	Percentage Of Revenue Contributed By Related Party PercentageOfRevenueContributedByRelatedParty	1
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	1400000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	487907000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	488252000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	327771000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	45000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2003000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	325813000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	487907000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	822000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	477000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	488252000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	327771000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	45000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2003000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	325813000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12249000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11327000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8682000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6841000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3567000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4486000	usd
CY2023	us-gaap	Depreciation Depreciation	1800000	usd
CY2022	us-gaap	Depreciation Depreciation	1800000	usd
CY2021	us-gaap	Depreciation Depreciation	1500000	usd
CY2023Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	3403000	usd
CY2022Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	3421000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1131000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1427000	usd
CY2023Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	2454000	usd
CY2022Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	959000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2997000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1078000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1272000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	173000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11257000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7058000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-161300000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9042000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7200000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1177000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1458000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10219000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8658000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	5455000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4545000	usd
CY2023Q4	plrx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	106000	usd
CY2023Q4	plrx	Long Term Debt Accretion Of Final Payment LongTermDebtAccretionOfFinalPayment	160000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	10054000	usd
CY2023Q4	plrx	Number Of Classes Of Stock Authorized NumberOfClassesOfStockAuthorized	2	class
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	plrx	Number Of Votes Per Share Of Common Stock NumberOfVotesPerShareOfCommonStock	1	research
CY2023	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12544982	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11435241	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-123300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1706000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44483000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22598000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10437000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-97300000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	plrx	Valuation Allowance As Percentage On Deferred Tax Assets ValuationAllowanceAsPercentageOnDeferredTaxAssets	1
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.067
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.073
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077
CY2023	plrx	Effective Income Tax Rate Reconciliation General Business Tax Credits Federal EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal	0.053
CY2022	plrx	Effective Income Tax Rate Reconciliation General Business Tax Credits Federal EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal	0.036
CY2021	plrx	Effective Income Tax Rate Reconciliation General Business Tax Credits Federal EffectiveIncomeTaxRateReconciliationGeneralBusinessTaxCreditsFederal	0.053
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.010
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.001
CY2023	plrx	Effective Income Tax Rate Reconciliation Nondeductible Executive Compensation Section162m Limitation EffectiveIncomeTaxRateReconciliationNondeductibleExecutiveCompensationSection162mLimitation	-0.038
CY2022	plrx	Effective Income Tax Rate Reconciliation Nondeductible Executive Compensation Section162m Limitation EffectiveIncomeTaxRateReconciliationNondeductibleExecutiveCompensationSection162mLimitation	0
CY2021	plrx	Effective Income Tax Rate Reconciliation Nondeductible Executive Compensation Section162m Limitation EffectiveIncomeTaxRateReconciliationNondeductibleExecutiveCompensationSection162mLimitation	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.302
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.305
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.332
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	78452000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	65689000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	29559000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	19688000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2211000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	387000	usd
CY2023Q4	plrx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	34769000	usd
CY2022Q4	plrx	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	13900000	usd
CY2023Q4	plrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	369000	usd
CY2022Q4	plrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1638000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8291000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5073000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	155001000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	108081000	usd
CY2023Q4	plrx	Deferred Tax Liabilities Fixed Asset Basis DeferredTaxLiabilitiesFixedAssetBasis	123000	usd
CY2022Q4	plrx	Deferred Tax Liabilities Fixed Asset Basis DeferredTaxLiabilitiesFixedAssetBasis	258000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	598000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	630000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	339000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1509000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1060000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2397000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	153941000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105684000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105684000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67684000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	48257000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	38000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	153941000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	105684000	usd
CY2023	plrx	Income Tax Examination Number Of Examinations Pending IncomeTaxExaminationNumberOfExaminationsPending	0	taxexamination
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5196000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3505000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2475000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1547000	usd
CY2023	plrx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	303000	usd
CY2022	plrx	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	144000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7974000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5196000	usd
CY2023	plrx	Contractual Arrangements Cancellation Period ContractualArrangementsCancellationPeriod	P30D
CY2023	plrx	Decrease In Right Of Use Assets And Liabilities From Lease Modifications DecreaseInRightOfUseAssetsAndLiabilitiesFromLeaseModifications	1800000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1382000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1382000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	64000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1318000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1360
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.082
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2771000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2501000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2300000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	766000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	721000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	949000	usd
CY2023	us-gaap	Lease Cost LeaseCost	3537000	usd
CY2022	us-gaap	Lease Cost LeaseCost	3222000	usd
CY2021	us-gaap	Lease Cost LeaseCost	3249000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	0	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8156985	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6432024	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3642021	shares
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001746473-24-000043-index-headers.html	Edgar Link	pending
0001746473-24-000043-index.html	Edgar Link	pending
0001746473-24-000043.txt	Edgar Link	pending
0001746473-24-000043-xbrl.zip	Edgar Link	pending
exhibit1017non-employeedir.htm	Edgar Link	pending
exhibit231auditorsconsent.htm	Edgar Link	pending
exhibit311ceocertification.htm	Edgar Link	pending
exhibit312cfocertification.htm	Edgar Link	pending
exhibit321ceoandcfocertifi.htm	Edgar Link	pending
exhibit97clawbackpolicy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plrx-20231231.htm	Edgar Link	pending
plrx-20231231.xsd	Edgar Link	pending
plrx-20231231_g1.jpg	Edgar Link	pending
plrx-20231231_g2.jpg	Edgar Link	pending
plrx-20231231_g3.jpg	Edgar Link	pending
plrx-20231231_g4.jpg	Edgar Link	pending
plrx-20231231_g5.jpg	Edgar Link	pending
plrx-20231231_g6.jpg	Edgar Link	pending
plrx-20231231_g7.jpg	Edgar Link	pending
plrx-20231231_g8.jpg	Edgar Link	pending
plrx-20231231_g9.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
plrx-20231231_def.xml	Edgar Link	unprocessable
plrx-20231231_cal.xml	Edgar Link	unprocessable
plrx-20231231_pre.xml	Edgar Link	unprocessable
plrx-20231231_lab.xml	Edgar Link	unprocessable
plrx-20231231_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

2024 Q1 Form 10-K Financial Statement

#000174647324000043 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX PLIANT THERAPEUTICS, INC. Stock $plrx

2024 Q1 Form 10-K Financial Statement

#000174647324000043 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx